Clinical Trials

500 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Neoplasms

NCT07124000 2026-03-31

DP-04

Recruiting

100 enrolled

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT06561685 2026-03-27

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

340 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT07259317 2026-03-27

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

60 enrolled

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

BreastGynecologicThoracic

45 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Recruiting

377 enrolled

GenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Neoplasms

NCT05873686 2026-03-03

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1 Recruiting

140 enrolled

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Mesothelioma, Neoplasms

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05365581 2026-02-13

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

398 enrolled

Adenocarcinoma

NCT07023315 2026-02-11

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

760 enrolled

Adenocarcinoma

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

DermatologicGastrointestinalThoracic

300 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06800313 2025-10-16

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1/2 Recruiting

33 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06605404 2025-08-14

Pan-tumor MRD Study

Recruiting

1,350 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma

NCT06038578 2025-08-03

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

146 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT06636682 2024-10-21

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

100 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06177041 2024-02-28

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

486 enrolled